A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
Clinical trial NCT07263386 · RECRUITING
Trial details
- NCT number
- NCT07263386
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-23
- Primary completion
- 2028-10-01
- Enrollment
- 460
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.